| Ayesha Naz Khalid, MD | |
|
59 Old Road To 9 Acre Cor, Suite 3, Concord, MA 01742-3317 | |
| (978) 287-7499 | |
| (978) 287-1191 |
| Full Name | Ayesha Naz Khalid |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Experience | 21 Years |
| Location | 59 Old Road To 9 Acre Cor, Concord, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528285921 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | MT181394 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cambridge Health Alliance | Cambridge, MA | Hospital |
| Boston Medical Center | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cambridge Public Health Commission | 8921910894 | 536 |
News Archive
Glissandra™ Skincare Inc. announced the global launch of its three signature anti-aging products concurrent with the Israel Cancer Research Fund's "Women of Action" awards luncheon honoring Beverly Cohen, Lisi Harrison, and Vivien Zighelboim, Ph.D, at the Four Seasons Hotel, Los Angeles at Beverly Hills.
In the first randomized controlled trial for adolescent bulimia nervosa to be completed in the US, researchers show that mobilizing parents to help an adolescent overcome the disorder can double the percentage of teens who were able to abstain from binge eating and purging after six months.
People with diabetic foot problems can lower their risk of leg amputation by relying on coordinated care that includes a podiatrist, according to a recent study. For instance, those with diabetes-related foot ulcers can reduce their risk of amputation by 31 percent.
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.
› Verified 3 days ago
| Entity Name | Medical Affiliates Of Cape Cod Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770534927 PECOS PAC ID: 3577471564 Enrollment ID: O20040510001010 |
News Archive
Glissandra™ Skincare Inc. announced the global launch of its three signature anti-aging products concurrent with the Israel Cancer Research Fund's "Women of Action" awards luncheon honoring Beverly Cohen, Lisi Harrison, and Vivien Zighelboim, Ph.D, at the Four Seasons Hotel, Los Angeles at Beverly Hills.
In the first randomized controlled trial for adolescent bulimia nervosa to be completed in the US, researchers show that mobilizing parents to help an adolescent overcome the disorder can double the percentage of teens who were able to abstain from binge eating and purging after six months.
People with diabetic foot problems can lower their risk of leg amputation by relying on coordinated care that includes a podiatrist, according to a recent study. For instance, those with diabetes-related foot ulcers can reduce their risk of amputation by 31 percent.
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.
› Verified 3 days ago
| Entity Name | Cambridge Public Health Commission |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932313228 PECOS PAC ID: 8921910894 Enrollment ID: O20050808000725 |
News Archive
Glissandra™ Skincare Inc. announced the global launch of its three signature anti-aging products concurrent with the Israel Cancer Research Fund's "Women of Action" awards luncheon honoring Beverly Cohen, Lisi Harrison, and Vivien Zighelboim, Ph.D, at the Four Seasons Hotel, Los Angeles at Beverly Hills.
In the first randomized controlled trial for adolescent bulimia nervosa to be completed in the US, researchers show that mobilizing parents to help an adolescent overcome the disorder can double the percentage of teens who were able to abstain from binge eating and purging after six months.
People with diabetic foot problems can lower their risk of leg amputation by relying on coordinated care that includes a podiatrist, according to a recent study. For instance, those with diabetes-related foot ulcers can reduce their risk of amputation by 31 percent.
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.
› Verified 3 days ago
| Entity Name | Emerson Practice Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508020199 PECOS PAC ID: 8123188117 Enrollment ID: O20081120000518 |
News Archive
Glissandra™ Skincare Inc. announced the global launch of its three signature anti-aging products concurrent with the Israel Cancer Research Fund's "Women of Action" awards luncheon honoring Beverly Cohen, Lisi Harrison, and Vivien Zighelboim, Ph.D, at the Four Seasons Hotel, Los Angeles at Beverly Hills.
In the first randomized controlled trial for adolescent bulimia nervosa to be completed in the US, researchers show that mobilizing parents to help an adolescent overcome the disorder can double the percentage of teens who were able to abstain from binge eating and purging after six months.
People with diabetic foot problems can lower their risk of leg amputation by relying on coordinated care that includes a podiatrist, according to a recent study. For instance, those with diabetes-related foot ulcers can reduce their risk of amputation by 31 percent.
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.
› Verified 3 days ago
| Entity Name | Physicians Of Cape Cod Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679832364 PECOS PAC ID: 9638326671 Enrollment ID: O20120828000193 |
News Archive
Glissandra™ Skincare Inc. announced the global launch of its three signature anti-aging products concurrent with the Israel Cancer Research Fund's "Women of Action" awards luncheon honoring Beverly Cohen, Lisi Harrison, and Vivien Zighelboim, Ph.D, at the Four Seasons Hotel, Los Angeles at Beverly Hills.
In the first randomized controlled trial for adolescent bulimia nervosa to be completed in the US, researchers show that mobilizing parents to help an adolescent overcome the disorder can double the percentage of teens who were able to abstain from binge eating and purging after six months.
People with diabetic foot problems can lower their risk of leg amputation by relying on coordinated care that includes a podiatrist, according to a recent study. For instance, those with diabetes-related foot ulcers can reduce their risk of amputation by 31 percent.
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ayesha Naz Khalid, MD 133 Ornac, Credentials Office, Concord, MA 01742-4159 Ph: (978) 287-3018 | Ayesha Naz Khalid, MD 59 Old Road To 9 Acre Cor, Suite 3, Concord, MA 01742-3317 Ph: (978) 287-7499 |
News Archive
Glissandra™ Skincare Inc. announced the global launch of its three signature anti-aging products concurrent with the Israel Cancer Research Fund's "Women of Action" awards luncheon honoring Beverly Cohen, Lisi Harrison, and Vivien Zighelboim, Ph.D, at the Four Seasons Hotel, Los Angeles at Beverly Hills.
In the first randomized controlled trial for adolescent bulimia nervosa to be completed in the US, researchers show that mobilizing parents to help an adolescent overcome the disorder can double the percentage of teens who were able to abstain from binge eating and purging after six months.
People with diabetic foot problems can lower their risk of leg amputation by relying on coordinated care that includes a podiatrist, according to a recent study. For instance, those with diabetes-related foot ulcers can reduce their risk of amputation by 31 percent.
Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.
› Verified 3 days ago
Dr. Daniel H Vogel, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 131 Ornac, Suite 490, Concord, MA 01742 Phone: 978-371-1400 Fax: 978-371-0246 | |
Mark Thomas Brown, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 54 Baker Avenue Ext Ste 303, Concord, MA 01742 Phone: 978-369-8780 | |
Monica Se-ting Lee, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 54 Baker Avenue Ext Ste 303, Concord, MA 01742 Phone: 978-369-8780 Fax: 978-369-1043 | |
Dr. George Kazda, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 59 Old Road To Nine Corner Suite 3, Emerson Ent Associates, Concord, MA 01742 Phone: 978-287-1119 | |
Jennifer Setlur, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 54 Baker Avenue Ext, Suite 303, Concord, MA 01742 Phone: 978-369-8780 | |
Michael H. Fattal, M.D, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 54 Baker Avenue Ext, Suite 303, Concord, MA 01742 Phone: 978-369-8780 Fax: 978-369-1043 |